Rafael (RFL) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
18 Nov, 2025Executive summary
Annual Meeting scheduled for January 8, 2026, to elect six directors, ratify the auditor, and approve an amendment to the 2021 Equity Incentive Plan increasing available shares by 1,000,000.
Voting rights are structured with Class A shares having three votes each and Class B shares one-tenth of a vote each; both classes vote as a single body.
Stockholders of record as of November 11, 2025, are eligible to vote in person or by proxy.
Voting matters and shareholder proposals
Proposals include election of six directors, ratification of CohnReznick LLP as auditor for FY 2026, and approval of an amendment to the 2021 Equity Incentive Plan.
Board recommends voting in favor of all proposals.
Shareholders may submit proposals for the 2027 meeting by July 31, 2026.
Board of directors and corporate governance
Board consists of six voting members, with a majority determined to be independent under NYSE standards.
Committees include Audit, Compensation, Corporate Governance, and Nominating, all comprised of independent directors.
Howard S. Jonas serves as Chairman, Executive Chairman, CEO, and President, and is the controlling shareholder.
Board and committees met regularly, with high attendance and active risk oversight roles.
Latest events from Rafael
- Net loss widened on higher R&D, cash at $37.8M, pivotal trial results due Q3.RFL
Q2 202616 Mar 2026 - $25M shelf offering to fund rare disease drug development and strategic initiatives.RFL
Registration Filing16 Dec 2025 - Shelf registration allows flexible capital raising with robust governance and indemnification.RFL
Registration Filing16 Dec 2025 - Net loss rose to $9.8M on higher R&D costs, with $45.5M in cash and Phase 3 trial ongoing.RFL
Q1 202612 Dec 2025 - Annual meeting to elect directors, ratify auditor, and expand equity plan by 750,000 shares.RFL
Proxy Filing1 Dec 2025 - Phase 3 trial progress and $25M rights offering drive improved financial outlook.RFL
Q4 202529 Oct 2025 - Q1 FY2025 net loss rose to $9.0M as focus shifts to Trappsol Cyclo™ post-merger.RFL
Q1 202513 Jun 2025 - FY2024 net loss reached $34.4M, with a major IPR&D charge and focus shifting to the Cyclo merger.RFL
Q4 202413 Jun 2025 - Net loss narrowed, cash strengthened, and pivotal Phase 3 trial results are imminent.RFL
Q3 202511 Jun 2025